Combines human immune organoid biology with generative AI to reduce immunogenicity risk in antibody development.
About
ALP Bio AG is a Swiss biotech startup developing a platform that integrates human immune organoid biology with generative AI. Their goal is to help antibody developers identify, understand, and reduce immunogenicity risk earlier in the drug development process. The platform leverages human tonsil organoid technology to model immune activity in vitro and employs AI models to learn from biological datasets. This hybrid approach aims to provide more clinically relevant signals for earlier decision-making in antibody development, supporting lead candidate screening, ADA risk stratification, and sequence optimization.
Tags
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does ALP Bio do?
ALP Bio AG is a Swiss biotech startup developing a platform that integrates human immune organoid biology with generative AI. Their goal is to help antibody developers identify, understand, and reduce immunogenicity risk earlier in the drug development process. The platform leverages human tonsil organoid technology to model immune activity in vitro and employs AI models to learn from biological datasets. This hybrid approach aims to provide more clinically relevant signals for earlier decision-…
How much funding has ALP Bio raised?
ALP Bio has raised a total of $2M in funding. The most recent round on record is Pre-Seed.
Where is ALP Bio headquartered?
ALP Bio is headquartered in Schlieren, Zurich, Switzerland.
When was ALP Bio founded?
ALP Bio was founded in 2025.
What industry does ALP Bio operate in?
ALP Bio operates in Biotechnology, Artificial Intelligence, Drug Discovery, Pharmaceuticals, Biotech, AI-Driven Drug Discovery.